Minireviews
Copyright ©2014 Baishideng Publishing Group Inc.
World J Gastrointest Oncol. Oct 15, 2014; 6(10): 393-402
Published online Oct 15, 2014. doi: 10.4251/wjgo.v6.i10.393
Table 1 Notable trial data for neoadjuvant and adjuvant therapies for gastric (or gastroesophageal) adenocarcinoma
TrialNo. of patientsMedian survival (mo)Overall survivalProgression-free survival
Neoadjuvant chemotherapy
EORTC 40954[20](2 yr)
5FU, cisplatin, folinic acid7264.6272.70%NR
Surgery alone7252.5369.90%NR
Perioperative chemotherapy
MAGIC Trial[26](5 yr)
ECF250NR36.30%NR
Surgery alone253NR23%NR
Fnlcc accord07/ffcd 9703[29](5 yr)(5 yr)
5FU, cisplatin113NR38%34%
Surgery alone111NR24%19%
Adjuvant chemoradiation
INT-0116 trial[32](3 yr)(3 yr)
5FU, CRT2813650%48%
Surgery alone2752741%31%
Artist trial[34](3 yr)
Capecitabine, cisplatin, CRT230NRNR78.20%
Capecitabine, cisplatin228NRNR74.20%
Adjuvant chemotherapy
ACTS-GC Trial[37](3, 5 yr)(5 yr)
S-1529NR80.1%, 71.7%65.40%
Surgery alone530NR70.1%, 61.1%53.10%
Classic trial[40](3 yr)(3 yr)
Capecitabine, oxaliplatin520NR83%74%
Surgery alone515NR78%59%